Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lung Neoplasms × 130-nm albumin-bound paclitaxel × Clear all

Phase

Phase 2 9 Phase 1/2 5 Phase 3 3 Phase 1 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 3 Breast Neoplasms 3 Pancreatic Neoplasms 2 Thymoma 1 Thymic epithelial tumor 1 Squamous NSCLC 1 Mediastinal Neoplasms 1 Lung Neoplasms 1 Gallbladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 6 Pemetrexed 5 Carboplatin 5 Paclitaxel 4 pembrolizumab 3 Magnetic Resonance Spectroscopy 3 Gemcitabine 3 Docetaxel 3 Radiotherapy 2 Leucovorin 2 Erlotinib Hydrochloride 2 Dexamethasone 2 pertuzumab 1 oblimersen 1 maimendongtang 1 endostar protein 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 cemiplimab 1 cediranib 1 auricularum 1 aumolertinib 1 anamorelin 1 Vitamin B 12 1 Vinorelbine 1 Trastuzumab 1 Specimen Handling 1 Sevoflurane 1 SR 48692 1 Rocuronium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07063745 2026-03-17

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡